A novel urine test may soon help doctors determine whether bladder cancer patients have residual disease after surgery and whether immunotherapy treatments are working, according to a recent announcement. The test, which screens for tumor DNA in urine, could provide a non-invasive way to monitor patients and guide treatment decisions.
Bladder cancer is one of the most common cancers, and standard treatment often involves surgical removal of tumors. However, residual cancer cells can remain, leading to recurrence. Currently, monitoring often relies on invasive cystoscopies or imaging. The new urine test offers a simpler alternative by detecting genetic material shed by cancer cells.
The research indicates that the test can identify patients who still have cancer after surgery, as well as those who respond well to immunotherapy drugs administered post-operatively. As more forms of immunotherapy are developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), the ability to quickly assess treatment efficacy becomes increasingly important.
“This test could revolutionize how we monitor bladder cancer patients,” said a researcher involved in the study. “Instead of waiting for symptoms or relying on invasive procedures, we can simply test urine and get a clear picture of the disease status.”
The implications for patients are significant. Early detection of residual cancer allows for timely intervention, potentially improving outcomes. For those on immunotherapy, the test could spare patients from ineffective treatments and their side effects, or signal when a change in therapy is needed.
From an industry perspective, the test could accelerate clinical trials by providing a rapid biomarker for drug response. Pharmaceutical companies developing new immunotherapies could use the test to better select patients and measure efficacy.
The development comes at a time when precision medicine is gaining traction. Liquid biopsies, which analyze bodily fluids for cancer DNA, are already used in some cancers, but this is one of the first applications specifically for bladder cancer monitoring.
While the test is not yet widely available, the researchers are optimistic about its potential. Further studies are needed to confirm its accuracy and reliability in larger patient populations. If successful, it could become a standard tool in bladder cancer management.
The news was disseminated by BioMedWire, a platform focused on biotechnology and life sciences developments.
